Overlapping substrate specificities of cytochrome P450 3A and P- glycoprotein for a novel cysteine protease inhibitor

Drug Metabolism and Disposition

Volumn 26, Issue 4, 1998, Pages 360-366

  Zhang, Yuanchao ^a   Guo, Xisheng ^a   Lin, Emil T ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZIDOPAMIL; AZIDOPINE; CYSTEINE PROTEINASE INHIBITOR; CYTOCHROME P450; GLYCOPROTEIN P; KO 2; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; DOG; DRUG ACTIVITY; DRUG BIOAVAILABILITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; KIDNEY CELL; LIVER MICROSOME METABOLISM; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIPEPTIDES; DOGS; HUMANS; KIDNEY; MICROSOMES, LIVER; MORPHOLINES; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS; STAPHYLOCOCCUS PHAGE 3A; TRYPANOSOMA; TRYPANOSOMA CRUZI;

EID: 0031944723     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Beck WT, Cirtain MC, Look AT and Ashmun RA (1986) Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res 46:778-784.
2. Benet LZ, Kroetz DL and Sheiner LB (1996a) Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Hardman JH, Limbird LE, Molinoff PB, Ruddon RW and Gilman AG eds) 9th Ed. pp 3-28, McGraw-Hill, New York.
3. Benet LZ, Wu CY, Hebert MF and Wacher VJ (1996b) Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Controlled Release 39:139-143.
4. Bontempi E, Martinez J and Cazzulo JJ (1989) Subcellular localization of a cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 33:43-48.
5. Bornheim LM and Correia MA (1989) Effect of cannabidiol on cytochrome P-450 isozymes. Biochem Pharmacol 38:2789-2794.
6. Chen WT (1992) Membrane proteases: Roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol 4:802-809.
7. Chiba M, Hensleigh M, Nishime JA, Balani SK and Lin JH (1996) Role of cytochrome P450 3A in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:307-314.
8. Clawson GA (1996) Protease inhibitors and carcinogenesis: A review. Cancer Invest 14:597-608.
9. DeClerk YA and Imren S (1994) Protease inhibitors: Role and potential therapeutic use in human cancer. Eur J Cancer 30A:2170-2180.
10. Elliott E and Sloane BF (1996) The cysteine protease cathepsin B in cancer. Perspect Drug Discovery Design 6:12-32.
11. Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58:137-171.
12. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP and Heben MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
13. Fritz P, Behrle E, Beaune P, Eichelbaum M and Kroemer HK (1993) Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: Immunohistochemical characterization of cytochrome P450 3A and glutathione-S-transferase. Histochemistry 99: 443-451.
14. Futscher BW. Foley NE, Gleason-Guzman MC, Meltzer PS, Sullivan DM and Dalton WS (1996) Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer 66:520-525.
15. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
16. Gorski JC, Jones DR, Wrighton SA and Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes: Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182.
17. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
18. Halpert JR, Guengerich FP, Bend JR and Correia MA (1994) Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125:163-175.
19. Hebert MF, Roberts JP, Prueksaritanont T and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
20. Hunter J, Jepson MA, Tsuruo T, Simmons NL and Hirst BH (1993) Functional expression of P-glycoprotein in apical membrane of human intestinal Caco-2 cells. J. Biol Chem 268:14991-14997.
21. Kivisto KT, Fritz P, Linder A, Friedel G, Beaune P and Kroemer HK (1995) Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochem Cell Biol 103:25-29.
22. Kumar GN, Rodrigues AD, Buko AM and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
23. Ling V (1995) P-glycoprotein: Its role in drug resistance. Am J Med 99:31S-34S.
24. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
25. McGrath ME, Eakin AE, Engel JC, McKerrow JH, Craik CS and Fletterick RJ (1995) The crystal structure of cruzain: A therapeutic target for Chagas' disease. J Mol Biol 247:251-259.
26. McKerrow JH, McGrath ME and Engel JC (1995) The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitol Today 11:279-282.
27. Murray GI, Shaw D, Weaver RJ, McKay JA, Ewen SW, Melvin WT and Burke MD (1994) Cytochrome P450 expression in oesophageal cancer. Gut 35:599-603.
28. Murray GI, Taylor VE, McKay JA, Weaver RJ, Ewen SW, Melvin WT and Burke MD (1995a) The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J Pathol 177:147-152.
29. Murray GI, Taylor VE, McKay JA, Weaver RJ, Ewen SW, Melvin WT and Burke MD (1995b) Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder. Int J Exp Pathol 76:271-276.
30. North M Jr, Mottram JC and Coombs CH (1990) Cysteine proteinases of parasitic protozoa. Parasitol Today 6:270-275.
31. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2370-2378.
32. Palmer JT, Rasnick D, Klaus JL and Bromme D (1995) Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 38:3193-3196.
33. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV and Willingham MC (1988) A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85:4486-4490.
34. Patel NH and Rothenberg ML (1994) Multidrug resistance in cancer chemotherapy. Invest New Drugs 12:1-13.
35. Prueksaritanont T, Dwyer LM, Balani SK and Theoharides AD (1994) In vitro metabolism of L-696,229, an HIV-1 reverse transcriptase inhibitor in rats and humans: Hepatic and extra-hepatic metabolism and identification of enzymes involved in the hepatic metabolism. Drug Metab Dispos 22:281-288.
36. Qian XD and Beck WT (1990) Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistance human leukemic cell lines. Cancer Res 50:1132-1137.
37. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ and Korzekwa KR (1994) O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Phamacol 45:352-358.
38. Scharfstein J, Schechter M, Senna M, Peralta JM, Mendonca-Previato L and Miles MA (1986) Trypanosoma cruzi: Characterization and isolation of a 57/51,000 m.w. surface glycoprotein (GP57/51) expressed by epimastigotes and bloodstream trypomastigotes. J Immunol 137: 1336-1341.
39. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE and Borst P (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033.
40. Schinkel AH, Wagenaar E, van Deemter L, Mol VA and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
41. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
42. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
43. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
44. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD and Carithers RL (1994a) Use of midazolam as a human cytochrome P450 3A probe. II. Characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271:557-566.
45. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD and Carithers RL (1994b) Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549-556.
46. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P and van Tellingen O (1996) Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 88:994-999.
47. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ and Beijnen JH (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181-1183.
48. Wacher VJ, Wu CY and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
49. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A-catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 11:921-924.
50. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58:492-497.
51. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P and Rahmani R (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem Pharmacol 45:853-861.
52. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y and Rahmani R (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 53:5121-5126.